Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Company Performance - Tango Therapeutics reported a quarterly loss of $0.35 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.32, representing an earnings surprise of -9.38% [1] - The company posted revenues of $4.12 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 47.46%, compared to revenues of $5.43 million a year ago [2] - Over the last four quarters, Tango Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Tango Therapeutics shares have declined approximately 24.6% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for stock performance [4] - The current consensus EPS estimate for the coming quarter is -$0.32 on revenues of $7.24 million, and for the current fiscal year, it is -$1.38 on revenues of $29.51 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Tango Therapeutics belongs, is currently in the top 28% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5] - The Zacks Rank for Tango Therapeutics is currently 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]